Experts Evaluate Use of Allergy And Asthma Devices – International Business Times AU


International Business Times AU

Experts Evaluate Use of Allergy And Asthma Devices
International Business Times AU
Inhalers and adrenalin auto-injectors are usually prescribed to patients with asthma and severe allergies, but instructions on how to use these devices are not often taught, according to various research groups. Incorrect use of these medical devices
Wrong-way drunk driver covers 50 kmThe Nation

all 2 news articles »

View full post on asthma – Google News

Energy Efficient Homes May Increase Asthma Risk – Business 2 Community


Business 2 Community

Energy Efficient Homes May Increase Asthma Risk
Business 2 Community
Asthma is a common chronic inflammatory respiratory disease characterized by swelling and narrowing of the airways, leading to wheezing, shortness of breath, chest tightness, and coughing. The causes of asthma are myriad, resulting from genetic and …
Asthma risks 'may be boosted by energy efficient homes'Medical News Today
Energy Efficient Homes May Be Linked To Increased Asthma RiskRedOrbit
Energy-efficient homes may boost asthma risksHealthCentral.com
Youth Health Magzine –The Fifth Estate –Free press journal
all 9 news articles »

View full post on asthma – Google News

UW-Madison awarded $70M NIH grant for asthma research – Milwaukee Business Journal


Milwaukee Business Journal

UW-Madison awarded $70M NIH grant for asthma research
Milwaukee Business Journal
The grantfrom the National Institute of Allergy and Infectious Diseases — the largest grant ever for the school — increases the total amount of NIH funding for the project, the Inner-City Asthma Consortium, to more than $190 million since 2002. The
Largest grant ever awarded to UW School of Medicine and Public Health will University of Wisconsin-Madison
UW Med School gets largest ever $70 million grantMadison.com

all 3 news articles »

View full post on asthma – Google News

American Lung Association and WellPoint Collaborate to Help Educate About … – Business Wire (press release)

American Lung Association and WellPoint Collaborate to Help Educate About
Business Wire (press release)
According to the Centers for Disease Control and Prevention, asthma is a common, potentially life threatening condition, affecting more than seven million children in the U.S. It is a prevalent issue in our nation's schools. In a typical classroom of

and more »

View full post on asthma – Google News

Research and Markets: GSK’s Flovent (Asthma) – Forecast and Market Analysis … – Business Wire (press release)

Research and Markets: GSK's Flovent (Asthma) – Forecast and Market Analysis
Business Wire (press release)
Originally approved by the Food and Drug Administration (FDA) in 1996, GSK's Flovent (fluticasone propionate) is a synthetic ICS therapy with potent anti-inflammatory activity. It is used for the maintenance treatment of asthma prophylactically in
Research and Markets: GSK's Bosatria (Mepolizumab) Asthma Treatment Rock Hill Herald (press release)

all 4 news articles »

View full post on asthma – Google News

Research and Markets: Roche’s Quilizumab (Asthma) – Forecast and Market … – Business Wire (press release)

Research and Markets: Roche's Quilizumab (Asthma) – Forecast and Market
Business Wire (press release)
IgE is important in the development of allergic asthma, as it binds to mast cells and basophils, which play a significant role in the pathogenesis of asthma. IgE ultimately triggers the release of histamines, prostaglandins, and leukotrienes, which
Research and Markets: Cinquil (Reslizumab) Asthma Treatment – Forecast and Rock Hill Herald (press release)
Research and Markets: Roche's Lebrikizumab (Asthma) Treatment – Forecast DigitalJournal.com

all 3 news articles »

View full post on asthma – Google News

Research and Markets: Roche/Genentech/Novartis’ Asthma Treatment – Xolair … – Business Wire (press release)

Research and Markets: Roche/Genentech/Novartis' Asthma Treatment – Xolair
Business Wire (press release)
Roche/Genentech/Novartis' Xolair (omalizumab) is currently the only FDA-approved biologic used in the treatment of asthma. This drug is a recombinant humanized mAb that binds and neutralizes IgE with the same high affinity as its cognate receptor, FceRI.
Research and Markets: Merck's Dulera Asthma Treatment – Forecast and Market DigitalJournal.com

all 2 news articles »

View full post on asthma – Google News

Pay Attention To Pollution To Combat Asthma Symptoms: Case Study – Business Insider


TheHealthSite

Pay Attention To Pollution To Combat Asthma Symptoms: Case Study
Business Insider
NEW YORK (Reuters Health) – For a 38-year old professor who cycled to work every day, asthma symptoms tended to be worst in midmorning and early afternoon on weekdays, but improved noticeably on weekends. Her doctor suspected the air pollution on …
Manage asthma better by reducing exposure to pollutionTheHealthSite

all 26 news articles »

View full post on asthma – Google News

Boston Children’s Hospital asthma initiative receives Medicaid endorsement – Boston Business Journal (blog)

Boston Children's Hospital asthma initiative receives Medicaid endorsement
Boston Business Journal (blog)
But a hospital initiative to provide some untraditional care to children with repeat asthma problems has helped significantly cut down on repeat ER visits. Now the state is endorsing the model through a pilot program that will offer bundled payments

View full post on asthma – Google News